Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
Inhalt nicht verfügbar. Bitte die Originalquelle aufrufen.
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.